Markers of systemic inflammatory response, including plasma C‐reactive protein (CRP) levels [12] and neutrophil‐to‐lymphocyte ratio (NLR) [13], have been demonstrated to be crucial in the progression and prognosis of ALS patients. This evidence concerns the gene CRP and amyotrophic lateral sclerosis.